Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.56 |
| ▸ | QPCT | Q16769 | 9/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | QPCTL | Q9NXS2 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1193158 | 0.85 | MAPT (0.45) | MMP12QPCTEGLN1RAB9AMAPT | |
| SCHEMBL11742410 | 0.77 | FGFR2 (0.49) | EGLN1NPC1RAB9AKMT2AMAPT | |
| SCHEMBL1193006 | 0.77 | MAPT (0.56) | MMP12QPCTNPC1MAPTQPCTL | |
| SCHEMBL225932 | 0.73 | MMP12 (1.00) | MMP12QPCTNPC1RAB9AKMT2A | |
| SCHEMBL225931 | 0.73 | MMP12 (0.73) | MMP12QPCTNPC1RAB9AKMT2A | |
| SCHEMBL29424791 | 0.73 | MMP12 (1.00) | MMP12QPCTNPC1RAB9AKMT2A | |
| SCHEMBL29919790 | 0.73 | MMP12 (0.73) | MMP12QPCTNPC1RAB9AKMT2A | |
| SCHEMBL953077 | 0.72 | MMP12 (0.56) | MMP12QPCTMAPTPOLB | |
| SCHEMBL2093317 | 0.71 | MMP12 (0.75) | MMP12QPCTNPC1RAB9AKMT2A | |
| SCHEMBL28292532 | 0.71 | MMP12 (0.60) | MMP12QPCTNPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11618744-B2 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2023-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11618744-B2 | Benzoimidazoles as prolyl hydroxylase inhibitors | P4HA1, PAH, EGLN3 | MMP12 1128/4885QPCT 1757/4885EGLN1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.